Published in Proc Natl Acad Sci U S A on September 22, 2008
Understanding biophysicochemical interactions at the nano-bio interface. Nat Mater (2009) 11.95
Biomolecular coronas provide the biological identity of nanosized materials. Nat Nanotechnol (2012) 3.48
Binding of blood proteins to carbon nanotubes reduces cytotoxicity. Proc Natl Acad Sci U S A (2011) 2.66
Rapid formation of plasma protein corona critically affects nanoparticle pathophysiology. Nat Nanotechnol (2013) 2.54
Minimal "Self" peptides that inhibit phagocytic clearance and enhance delivery of nanoparticles. Science (2013) 2.42
Role of cell cycle on the cellular uptake and dilution of nanoparticles in a cell population. Nat Nanotechnol (2011) 1.90
PEGylated PRINT nanoparticles: the impact of PEG density on protein binding, macrophage association, biodistribution, and pharmacokinetics. Nano Lett (2012) 1.77
The new toxicology of sophisticated materials: nanotoxicology and beyond. Toxicol Sci (2010) 1.71
An index for characterization of nanomaterials in biological systems. Nat Nanotechnol (2010) 1.69
Interaction of nanoparticles with proteins: relation to bio-reactivity of the nanoparticle. J Nanobiotechnology (2013) 1.57
Interactions of engineered nanomaterials in physiological media and implications for in vitro dosimetry. Nanotoxicology (2012) 1.54
Computational model for nanocarrier binding to endothelium validated using in vivo, in vitro, and atomic force microscopy experiments. Proc Natl Acad Sci U S A (2010) 1.53
Binding affinity and kinetic analysis of targeted small molecule-modified nanoparticles. Bioconjug Chem (2010) 1.52
Understanding and overcoming major barriers in cancer nanomedicine. Nanomedicine (Lond) (2010) 1.51
State-of-the-art in design rules for drug delivery platforms: lessons learned from FDA-approved nanomedicines. J Control Release (2014) 1.46
Silica coating influences the corona and biokinetics of cerium oxide nanoparticles. Part Fibre Toxicol (2015) 1.45
An in vivo and in vitro toxicological characterisation of realistic nanoscale CeO₂ inhalation exposures. Nanotoxicology (2012) 1.43
Modeling the time evolution of the nanoparticle-protein corona in a body fluid. PLoS One (2010) 1.34
Hydroxyapatite nanoparticle-containing scaffolds for the study of breast cancer bone metastasis. Biomaterials (2011) 1.32
Particle size-dependent and surface charge-dependent biodistribution of gold nanoparticles after intravenous administration. Eur J Pharm Biopharm (2010) 1.29
TAT peptide-functionalized gold nanostars: enhanced intracellular delivery and efficient NIR photothermal therapy using ultralow irradiance. J Am Chem Soc (2012) 1.28
Functionalized carbon nanotubes: biomedical applications. Int J Nanomedicine (2012) 1.27
Drug delivery trends in clinical trials and translational medicine: challenges and opportunities in the delivery of nucleic acid-based therapeutics. J Pharm Sci (2011) 1.24
Cytotoxicity screening of 23 engineered nanomaterials using a test matrix of ten cell lines and three different assays. Part Fibre Toxicol (2011) 1.21
Transcytosis and brain uptake of transferrin-containing nanoparticles by tuning avidity to transferrin receptor. Proc Natl Acad Sci U S A (2013) 1.19
Size and surface charge of gold nanoparticles determine absorption across intestinal barriers and accumulation in secondary target organs after oral administration. Nanotoxicology (2011) 1.19
A biodegradable nanoparticle platform for the induction of antigen-specific immune tolerance for treatment of autoimmune disease. ACS Nano (2014) 1.16
HPMA-oligolysine copolymers for gene delivery: optimization of peptide length and polymer molecular weight. J Control Release (2011) 1.15
Silver nanoparticle protein corona composition in cell culture media. PLoS One (2013) 1.13
Cholesterol derivatives based charged liposomes for doxorubicin delivery: preparation, in vitro and in vivo characterization. Theranostics (2012) 1.13
Engineering the nanoparticle-protein interface: applications and possibilities. Curr Opin Chem Biol (2010) 1.12
Single nanoparticle detectors for biological applications. Nanoscale (2012) 1.10
Scavenger receptor mediated endocytosis of silver nanoparticles into J774A.1 macrophages is heterogeneous. ACS Nano (2012) 1.09
New views on cellular uptake and trafficking of manufactured nanoparticles. J R Soc Interface (2013) 1.09
The adsorption of biomolecules to multi-walled carbon nanotubes is influenced by both pulmonary surfactant lipids and surface chemistry. J Nanobiotechnology (2010) 1.08
Solubility of nano-zinc oxide in environmentally and biologically important matrices. Environ Toxicol Chem (2012) 1.08
Fabrication of corona-free nanoparticles with tunable hydrophobicity. ACS Nano (2014) 1.07
Chemical basis of interactions between engineered nanoparticles and biological systems. Chem Rev (2014) 1.07
Risks from accidental exposures to engineered nanoparticles and neurological health effects: a critical review. Part Fibre Toxicol (2010) 1.07
Protein corona composition of superparamagnetic iron oxide nanoparticles with various physico-chemical properties and coatings. Sci Rep (2014) 1.06
Quantitative proteomics analysis of adsorbed plasma proteins classifies nanoparticles with different surface properties and size. Proteomics (2011) 1.06
Comparison of nanotube-protein corona composition in cell culture media. Small (2013) 1.06
Engineered nanomaterials: exposures, hazards, and risk prevention. J Occup Med Toxicol (2011) 1.05
Amorphous silica nanoparticles trigger nitric oxide/peroxynitrite imbalance in human endothelial cells: inflammatory and cytotoxic effects. Int J Nanomedicine (2011) 1.04
Odyssey of a cancer nanoparticle: from injection site to site of action. Nano Today (2012) 1.04
Adsorption of surfactant lipids by single-walled carbon nanotubes in mouse lung upon pharyngeal aspiration. ACS Nano (2012) 1.04
Body-on-a-chip simulation with gastrointestinal tract and liver tissues suggests that ingested nanoparticles have the potential to cause liver injury. Lab Chip (2014) 1.04
Air-blood barrier translocation of tracheally instilled gold nanoparticles inversely depends on particle size. ACS Nano (2013) 1.03
Dynamic factors controlling targeting nanocarriers to vascular endothelium. Curr Drug Metab (2012) 1.02
The effect of surface nanometre-scale morphology on protein adsorption. PLoS One (2010) 1.01
Nanoparticle size and surface charge determine effects of PAMAM dendrimers on human platelets in vitro. Mol Pharm (2011) 1.01
The optical, photothermal, and facile surface chemical properties of gold and silver nanoparticles in biodiagnostics, therapy, and drug delivery. Arch Toxicol (2014) 1.01
Physicochemical characteristics of nanomaterials that affect pulmonary inflammation. Part Fibre Toxicol (2014) 1.01
Nanoparticle-cell interactions: molecular structure of the protein corona and cellular outcomes. Acc Chem Res (2014) 0.99
Minimal mesoscale model for protein-mediated vesiculation in clathrin-dependent endocytosis. PLoS Comput Biol (2010) 0.99
Altered characteristics of silica nanoparticles in bovine and human serum: the importance of nanomaterial characterization prior to its toxicological evaluation. Part Fibre Toxicol (2013) 0.98
Charged gold nanoparticles with essentially zero serum protein adsorption in undiluted fetal bovine serum. J Am Chem Soc (2013) 0.98
A general mechanism for intracellular toxicity of metal-containing nanoparticles. Nanoscale (2014) 0.98
In situ measurement of bovine serum albumin interaction with gold nanospheres. Langmuir (2012) 0.98
Quantum dots as a platform for nanoparticle drug delivery vehicle design. Adv Drug Deliv Rev (2012) 0.97
Material nanosizing effect on living organisms: non-specific, biointeractive, physical size effects. J R Soc Interface (2009) 0.97
Lung exposure of titanium dioxide nanoparticles induces innate immune activation and long-lasting lymphocyte response in the Dark Agouti rat. J Immunotoxicol (2011) 0.97
Nanoparticle toxicity by the gastrointestinal route: evidence and knowledge gaps. Int J Biomed Nanosci Nanotechnol (2013) 0.96
Widespread nanoparticle-assay interference: implications for nanotoxicity testing. PLoS One (2014) 0.96
Effects of surface functional groups on the formation of nanoparticle-protein corona. Appl Phys Lett (2012) 0.96
Biomolecular corona on nanoparticles: a survey of recent literature and its implications in targeted drug delivery. Front Chem (2014) 0.95
Quantification of the internalization patterns of superparamagnetic iron oxide nanoparticles with opposite charge. J Nanobiotechnology (2012) 0.95
Identifying new therapeutic targets via modulation of protein corona formation by engineered nanoparticles. PLoS One (2012) 0.95
Effect of cholesterol nanodomains on the targeting of lipid-based gene delivery in cultured cells. Mol Pharm (2010) 0.95
Nanocarrier Hydrodynamics and Binding in Targeted Drug Delivery: Challenges in Numerical Modeling and Experimental Validation. J Nanotechnol Eng Med (2013) 0.95
Amorphous silica nanoparticles aggregate human platelets: potential implications for vascular homeostasis. Int J Nanomedicine (2012) 0.95
Protein binding modulates the cellular uptake of silver nanoparticles into human cells: implications for in vitro to in vivo extrapolations? Toxicol Lett (2013) 0.94
A condensation-ordering mechanism in nanoparticle-catalyzed peptide aggregation. PLoS Comput Biol (2009) 0.94
Digital sensing and sizing of vesicular stomatitis virus pseudotypes in complex media: a model for Ebola and Marburg detection. ACS Nano (2014) 0.93
Proteomic analysis of serum opsonins impacting biodistribution and cellular association of porous silicon microparticles. Mol Imaging (2011) 0.92
Overview of the main methods used to combine proteins with nanosystems: absorption, bioconjugation, and encapsulation. Int J Nanomedicine (2010) 0.92
Bions: a family of biomimetic mineralo-organic complexes derived from biological fluids. PLoS One (2013) 0.91
Complement proteins bind to nanoparticle protein corona and undergo dynamic exchange in vivo. Nat Nanotechnol (2016) 0.91
Ultrasmall glutathione-protected gold nanoclusters as next generation radiotherapy sensitizers with high tumor uptake and high renal clearance. Sci Rep (2015) 0.90
Direct observation of a single nanoparticle-ubiquitin corona formation. Nanoscale (2013) 0.90
Superparamagnetic iron oxide nanoparticles: promises for diagnosis and treatment of cancer. Int J Mol Epidemiol Genet (2011) 0.90
Nanoparticles and the blood coagulation system. Part II: safety concerns. Nanomedicine (Lond) (2013) 0.90
Probing of the assembly structure and dynamics within nanoparticles during interaction with blood proteins. ACS Nano (2012) 0.90
The nano-plasma interface: Implications of the protein corona. Colloids Surf B Biointerfaces (2014) 0.90
Detoxifying antitumoral drugs via nanoconjugation: the case of gold nanoparticles and cisplatin. PLoS One (2012) 0.90
Cationic lipid-coated PEI/DNA polyplexes with improved efficiency and reduced cytotoxicity for gene delivery into mesenchymal stem cells. Int J Nanomedicine (2012) 0.89
Terminal supraparticle assemblies from similarly charged protein molecules and nanoparticles. Nat Commun (2014) 0.89
Quantitative profiling of the protein coronas that form around nanoparticles. Nat Protoc (2014) 0.89
Macrophage scavenger receptor A mediates the uptake of gold colloids by macrophages in vitro. Nanomedicine (Lond) (2011) 0.89
Engineered iron-oxide-based nanoparticles as enhanced T1 contrast agents for efficient tumor imaging. ACS Nano (2013) 0.89
On-chip bioorthogonal chemistry enables immobilization of in situ modified nanoparticles and small molecules for label-free monitoring of protein binding and reaction kinetics. Lab Chip (2012) 0.89
Engineered nanomaterials in food: implications for food safety and consumer health. Int J Environ Res Public Health (2014) 0.89
Formation of nano-bio-complex as nanomaterials dispersed in a biological solution for understanding nanobiological interactions. Sci Rep (2012) 0.89
The interplay of monolayer structure and serum protein interactions on the cellular uptake of gold nanoparticles. Small (2012) 0.89
Bioavailability, distribution and clearance of tracheally-instilled and gavaged uncoated or silica-coated zinc oxide nanoparticles. Part Fibre Toxicol (2014) 0.88
Nanotoxicity assessment: all small talk? Adv Drug Deliv Rev (2009) 0.88
Nanoparticle-nanoparticle interactions in biological media by atomic force microscopy. Langmuir (2013) 0.88
High-Density Lipoproteins: Nature's Multifunctional Nanoparticles. ACS Nano (2016) 0.87
Protein bio-corona: critical issue in immune nanotoxicology. Arch Toxicol (2016) 0.87
Interaction of β-sheet folds with a gold surface. PLoS One (2011) 0.87
Mass spectrometric sequencing of proteins silver-stained polyacrylamide gels. Anal Chem (1996) 45.70
The human plasma proteome: history, character, and diagnostic prospects. Mol Cell Proteomics (2002) 16.08
Method to correlate tandem mass spectra of modified peptides to amino acid sequences in the protein database. Anal Chem (1995) 9.39
Understanding the nanoparticle-protein corona using methods to quantify exchange rates and affinities of proteins for nanoparticles. Proc Natl Acad Sci U S A (2007) 7.50
Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL. J Clin Invest (2007) 5.38
Detailed identification of plasma proteins adsorbed on copolymer nanoparticles. Angew Chem Int Ed Engl (2007) 3.41
Selective IgG subclass deficiency: quantification and clinical relevance. Clin Exp Immunol (1990) 3.20
Lipoproteomics II: mapping of proteins in high-density lipoprotein using two-dimensional gel electrophoresis and mass spectrometry. Proteomics (2005) 1.88
Proteomic analysis of high-density lipoprotein. Proteomics (2006) 1.82
Nanoparticles with decreasing surface hydrophobicities: influence on plasma protein adsorption. Int J Pharm (2000) 1.73
Functional groups on polystyrene model nanoparticles: influence on protein adsorption. J Biomed Mater Res A (2003) 1.69
Influence of surface charge density on protein adsorption on polymeric nanoparticles: analysis by two-dimensional electrophoresis. Eur J Pharm Biopharm (2002) 1.55
Analysis of plasma protein adsorption on polymeric nanoparticles with different surface characteristics. J Biomed Mater Res (1998) 1.51
Mass spectrometry-based analytical tools for the molecular protein characterization of human plasma lipoproteins. Proteomics (2005) 1.49
Lipoproteomics I: mapping of proteins in low-density lipoprotein using two-dimensional gel electrophoresis and mass spectrometry. Proteomics (2005) 1.44
Influence of fluorescent labelling of polystyrene particles on phagocytic uptake, surface hydrophobicity, and plasma protein adsorption. Pharm Res (1997) 1.37
Diverse range of small peptides associated with high-density lipoprotein. Biochem Biophys Res Commun (2005) 1.34
Proteomic analysis of human very low-density lipoprotein by two-dimensional gel electrophoresis and MALDI-TOF/TOF. Proteomics (2007) 1.10
HDL proteomics: pot of gold or Pandora's box? J Clin Invest (2007) 1.08
Understanding the nanoparticle-protein corona using methods to quantify exchange rates and affinities of proteins for nanoparticles. Proc Natl Acad Sci U S A (2007) 7.50
Biomolecular coronas provide the biological identity of nanosized materials. Nat Nanotechnol (2012) 3.48
Detailed identification of plasma proteins adsorbed on copolymer nanoparticles. Angew Chem Int Ed Engl (2007) 3.41
Transferrin-functionalized nanoparticles lose their targeting capabilities when a biomolecule corona adsorbs on the surface. Nat Nanotechnol (2013) 3.39
The La protein. Annu Rev Biochem (2001) 3.32
Nucleation of protein fibrillation by nanoparticles. Proc Natl Acad Sci U S A (2007) 3.23
Physical-chemical aspects of protein corona: relevance to in vitro and in vivo biological impacts of nanoparticles. J Am Chem Soc (2011) 3.19
What the cell "sees" in bionanoscience. J Am Chem Soc (2010) 3.07
Effects of the presence or absence of a protein corona on silica nanoparticle uptake and impact on cells. ACS Nano (2012) 2.59
Protein-nanoparticle interactions: opportunities and challenges. Chem Rev (2011) 2.34
The nanoparticle-protein complex as a biological entity; a complex fluids and surface science challenge for the 21st century. Adv Colloid Interface Sci (2007) 2.22
The evolution of the protein corona around nanoparticles: a test study. ACS Nano (2011) 2.05
Detecting cryptic epitopes created by nanoparticles. Sci STKE (2006) 2.02
Protein-nanoparticle interactions: What does the cell see? Nat Nanotechnol (2009) 2.00
Role of cell cycle on the cellular uptake and dilution of nanoparticles in a cell population. Nat Nanotechnol (2011) 1.90
Inhibition of amyloid beta protein fibrillation by polymeric nanoparticles. J Am Chem Soc (2008) 1.60
Regulator of G-protein signaling 18 integrates activating and inhibitory signaling in platelets. Blood (2012) 1.59
Complete high-density lipoproteins in nanoparticle corona. FEBS J (2009) 1.47
Nanoparticle adhesion to the cell membrane and its effect on nanoparticle uptake efficiency. J Am Chem Soc (2013) 1.44
Quantification of nanoparticle uptake by cells using an unbiased sampling method and electron microscopy. Nanomedicine (Lond) (2011) 1.43
Designing the nanoparticle-biomolecule interface for "targeting and therapeutic delivery". J Control Release (2012) 1.41
Exposure assessment: recommendations for nanotechnology-based pesticides. Int J Occup Environ Health (2011) 1.39
Minimal analytical characterization of engineered nanomaterials needed for hazard assessment in biological matrices. Nanotoxicology (2010) 1.38
Systematic investigation of the thermodynamics of HSA adsorption to N-iso-propylacrylamide/N-tert-butylacrylamide copolymer nanoparticles. Effects of particle size and hydrophobicity. Nano Lett (2007) 1.37
Effects of transport inhibitors on the cellular uptake of carboxylated polystyrene nanoparticles in different cell lines. PLoS One (2011) 1.36
Reversible versus irreversible binding of transferrin to polystyrene nanoparticles: soft and hard corona. ACS Nano (2012) 1.35
Experimental and theoretical comparison of intracellular import of polymeric nanoparticles and small molecules: toward models of uptake kinetics. Nanomedicine (2011) 1.35
Modeling the time evolution of the nanoparticle-protein corona in a body fluid. PLoS One (2010) 1.34
Serum heat inactivation affects protein corona composition and nanoparticle uptake. Biomaterials (2010) 1.34
In vivo protein biotinylation for identification of organ-specific antigens accessible from the vasculature. Nat Methods (2005) 1.32
A lupus-like syndrome develops in mice lacking the Ro 60-kDa protein, a major lupus autoantigen. Proc Natl Acad Sci U S A (2003) 1.31
Emerging methods and tools for environmental risk assessment, decision-making, and policy for nanomaterials: summary of NATO Advanced Research Workshop. J Nanopart Res (2008) 1.28
Reproducible comet assay of amorphous silica nanoparticles detects no genotoxicity. Nano Lett (2008) 1.25
Quantitative assessment of the comparative nanoparticle-uptake efficiency of a range of cell lines. Small (2011) 1.25
The biomolecular corona is retained during nanoparticle uptake and protects the cells from the damage induced by cationic nanoparticles until degraded in the lysosomes. Nanomedicine (2013) 1.25
Time and space resolved uptake study of silica nanoparticles by human cells. Mol Biosyst (2010) 1.25
Fate and effects of CeO2 nanoparticles in aquatic ecotoxicity tests. Environ Sci Technol (2009) 1.20
Nanotoxicology: nanoparticles reconstruct lipids. Nat Nanotechnol (2009) 1.19
Dynamic force sensing of filamin revealed in single-molecule experiments. Proc Natl Acad Sci U S A (2012) 1.17
Modulation of gene expression by hypoxia in human umbilical cord vein endothelial cells: A transcriptomic and proteomic study. Proteomics (2004) 1.14
Dual effect of amino modified polystyrene nanoparticles on amyloid β protein fibrillation. ACS Chem Neurosci (2010) 1.14
Nanopesticides: guiding principles for regulatory evaluation of environmental risks. J Agric Food Chem (2014) 1.12
Therapeutic nanoparticles in clinics and under clinical evaluation. Nanomedicine (Lond) (2013) 1.11
Surface-induced changes in protein adsorption and implications for cellular phenotypic responses to surface interaction. Biomaterials (2006) 1.10
Nanobiotechnology: nanoparticle coronas take shape. Nat Nanotechnol (2011) 1.09
Purification of biotinylated proteins on streptavidin resin: a protocol for quantitative elution. Proteomics (2004) 1.08
Classification framework for graphene-based materials. Angew Chem Int Ed Engl (2014) 1.06
Novel method to prepare morphologically rich polymeric surfaces for biomedical applications via phase separation and arrest of microgel particles. J Phys Chem B (2006) 1.03
A chemical proteomics approach for the identification of accessible antigens expressed in human kidney cancer. Mol Cell Proteomics (2006) 1.03
Phase equilibria and glass transition in colloidal systems with short-ranged attractive interactions: application to protein crystallization. Phys Rev E Stat Nonlin Soft Matter Phys (2002) 1.03
In vitro developmental toxicity test detects inhibition of stem cell differentiation by silica nanoparticles. Toxicol Appl Pharmacol (2009) 1.02
Nanomaterial categorization for assessing risk potential to facilitate regulatory decision-making. ACS Nano (2015) 1.01
Correlation signature of the macroscopic states of the gene regulatory network in cancer. Proc Natl Acad Sci U S A (2009) 1.01
Interaction of soft condensed materials with living cells: phenotype/transcriptome correlations for the hydrophobic effect. Proc Natl Acad Sci U S A (2003) 1.00
Protein fibrillation and nanoparticle interactions: opportunities and challenges. Nanoscale (2013) 1.00
Surface coatings shape the protein corona of SPIONs with relevance to their application in vivo. Langmuir (2012) 0.99
High-speed imaging of Rab family small GTPases reveals rare events in nanoparticle trafficking in living cells. ACS Nano (2012) 0.98
Activation of stress-related signalling pathway in human cells upon SiO2 nanoparticles exposure as an early indicator of cytotoxicity. J Nanobiotechnology (2011) 0.97
Structural changes in apolipoproteins bound to nanoparticles. Langmuir (2011) 0.96
A new methodology for studying nanoparticle interactions in biological systems: dispersing titania in biocompatible media using chemical stabilisers. Nanoscale (2011) 0.96
Identification and relative quantification of membrane proteins by surface biotinylation and two-dimensional peptide mapping. Proteomics (2005) 0.95
Nanoscale reference materials for environmental, health and safety measurements: needs, gaps and opportunities. Nanotoxicology (2012) 0.94
TGF-beta1-induced thrombospondin-1 expression through the p38 MAPK pathway is abolished by fluvastatin in human coronary artery smooth muscle cells. Vascul Pharmacol (2006) 0.93
Suppression of nanoparticle cytotoxicity approaching in vivo serum concentrations: limitations of in vitro testing for nanosafety. Nanoscale (2014) 0.93
Cationic nanoparticles induce caspase 3-, 7- and 9-mediated cytotoxicity in a human astrocytoma cell line. Nanotoxicology (2010) 0.93
The Germinal centre-derived lymphomas seen through their cellular microenvironment. Br J Haematol (2008) 0.91
Ultrafast folding kinetics and cooperativity of villin headpiece in single-molecule force spectroscopy. Proc Natl Acad Sci U S A (2013) 0.91
Genotoxicity evaluation of amorphous silica nanoparticles of different sizes using the micronucleus and the plasmid lacZ gene mutation assay. Nanotoxicology (2010) 0.91